Proteoform Scientific Inc. is a Canadian-based developer and manufacturer of innovative solutions and cutting-edge devices in the ever-growing omics fields of science proteomics.
Launched in 2018, with a carefully selected, unrivalled team of science and business experts, the company was assembled to bring our flagship product, the ProTrap XG, to life. Today, the focus remains on creating better tools for better science.
We all came together for one reason and one reason only – to empower research.
By creating better, faster, more efficient solutions, we’re helping researchers improve sample preparation workflows for better analysis, leading to better results. Our goal is to help revolutionize disease analysis leading to precision and personalized treatments, while contributing to improved health outcomes.
Kent MacLeanPresident & CEO
A senior business development leader and visionary, Kent joined Proteoform Scientific in 2018 to fully commercialize the company and lead strategic growth initiatives. Kent brings more than 30 years of global experience in finance, operations, and business development to our Company. With in-depth knowledge and hands-on experience in both start-up and high growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements. Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long term client and partner relationships built on trust, which all contribute to successful business ventures.
Alan Doucette, PhDChief Scientist
Dr. Alan Doucette is internationally recognized as a leader in proteomics front-end sample preparation, particularly as it applies to the analysis of intact proteins by top-down MS.
He is credited with 35 peer-reviewed publications in the field of proteomics and analytical mass spectrometry and has made over 100 presentations at national and international scientific research conferences. He also has three patents and two license agreements for product commercialization. Since 2004, Alan has and continues to serve as a Professor of Chemistry at Dalhousie University. His program focuses on the development of advanced innovative technologies to improve advanced proteome characterization by mass spectrometry (MS).
Victoria Miller, PhDSenior Scientist
Victoria Miller, Proteoform Scientific’s Senior Scientist, brings strong experience in multiple protein purification techniques and the performance of electrophoretic, chromogenic, and immunological assays to our team. With over 25 years of experience in both industry and academia, Victoria has been a research and development scientist and academic laboratory manager. She also served in project management and regulatory roles with a medical device company. Victoria holds a PhD from Dalhousie University, where her thesis project focused on protein biochemistry. She also holds a MSc from Dalhousie University and a BSc from McMaster University.
Pattie ReynoldsManager, Strategic Initiatives
Pattie leads Proteoform Scientific’s strategic initiatives with a focus on manufacturing and assembly efficiency improvements, logistics, processes, quality controls, and new projects around product evaluation and development. An industrial engineer, with over 24 years of experience in manufacturing, Pattie has worked in a broad range of industry sectors including aerospace, shipbuilding, health and beauty, food, and life sciences. Through her various roles in operations and manufacturing, Patricia has gained both strategic and hands-on experience in optimizing contract manufacturing, supply chain, warehousing and logistics, product quality assurance processes, and streamlining productivity and cost strategies to support business growth.
Erin CluneyBusiness Development Manager
Erin is our Business Development Manager. With a successful track record of key account management and sales in the life sciences sector since 2002, Erin leads Proteoform Scientific’s customer-focused initiatives and develops and nurtures distribution channel partner relationships. Before joining our team in 2020, Erin worked in the pharmaceutical industry, holding roles with Janssen, Aspen Pharmacare, Boehringer Ingelheim, and GlaxoSmithKlein. She gained experience across multiple disease areas including oncology, cardiology, and endocrinology while building an excellent knowledge base and clinical aptitude, participating in product launches, and facilitating customer training.
Andrea YoungManager, Marketing Communications
Andrea has 25+ years of strategic and tactical marketing communications, as well as sales enablement experience in biotech and other emerging growth industries. Andrea joined Proteoform Scientific in 2019 and previously spent 14 years in the medical device industry. She is a results-oriented marketing communications professional with both implementation and strategic experience across a range of industries and dynamic work environments, including start-ups and emerging growth companies. With over 25 years of hands-on industry experience in biotech and life sciences, software development, telecommunications, not-for-profit, and professional services, Andrea brings a consultative approach to shaping complex and technical details into digestible, relevant messages, which support Proteoform Scientific’s business development and sale enablement strategies.
Alex DunneManager, Accounting & Reporting
Alex joined our team in 2020 as the Manager of Accounting & Reporting. He leads the day-to-day financial activities of the Company and provides key reporting, analysis, and metrics to support Proteoform Scientific’s business operations and growth initiatives. Alex is a recent graduate of Queen’s University with a Master’s degree in International Business where he focused on strategic management for multinationals and virtual team dynamics. Alex also holds a BBA (Accounting) and his previous work experience includes consulting, project management, and business management.
Jessica NickersonResearch Associate
A Ph.D candidate at Dalhousie University, Jessica has presented posters at various proteomics conferences, with research focused on front-end sample prep. Jessica’s research focuses on protein precipitation-based sample preparation for proteomic analysis by mass spectrometry. She completed a B.Sc in 2017 and is now a Ph.D candidate under the supervision of Dr. Alan Doucette. She has presented at numerous international proteomics and mass spectrometry conferences including US HUPO, ASMS, and HUPO International and recently published a research article in the Journal of Proteome Research as first author. In addition to her graduate studies, Jessica works with Proteoform Scientific as a Research Associate contributing to the initial design and ongoing advancements of the ProTrap XG.
OUr Directors & Advisors
Ali RiazCo-founder & Executive Chairman
A proven leader and mentor with M&A transactions of more than $2.5 billion and a $1.3 billion exit, Ali was also President of FAST from 2000-2006, before selling the company to Microsoft. As Founder & CEO of Attivo Inc., Ali has raised more than $100 million to fuel growth and execute strategy.
Peter HickeyCo-founder & Executive Director
With over 18 years of experience leading globally-focused technology companies, Peter has worked with a number of large-scale clients including global, publicly traded firms and government organizations as well as smaller, privately-held companies. He is the CEO of Adaptiiv, co-founder of Oris4, and former CEO of Coemergence and director of a Hong Kong-based financial services firm.
Kent MacLeanPresident & CEO
A senior business development leader and visionary, Kent brings more than 30 years of global experience in finance, operations and business development to our Company. With in-depth knowledge and hands-on experience in both start-up and high growth organizations in Canada, the United States, Caribbean, and Latin America, Kent has a proven track record in accelerated business achievements. Kent focuses on creating highly effective teams, expanding international markets, developing and nurturing key profitable business networks, and securing long term client and partner relationships built on trust, which all contribute to successful business ventures.
Alan DoucetteDirector & Chief Scientist
Alan is internationally recognized as a leader in proteomics front-end sample preparation, particularly as it applies to the analysis of intact proteins by top-down MS. He is credited with 35 peer-reviewed publications in the field of proteomics and analytical mass spectrometry and has made over 100 presentations at national and international scientific research conferences. He also has three patents and two license agreements for product commercialization. Since 2004, Alan has and continues to serve as a Professor of Chemistry at Dalhousie University. His lab focuses on the development of innovative technologies to advance proteome characterization by mass spectrometry.
For over a decade, Kevin has been commercializing research generated in academic institutions. With a focus on physical science, his successes include medical devices and chemical compounds as well as various scientific equipment. He also has significant experience in accessing and leveraging non-dilutive funds to advance early-stage technology development.
Neil is an experienced surgeon and business leader with a demonstrated history in the healthcare industry. He has worked in both the private and public sector as a board chairman and executive chairman of a publicly traded company. Neil also has experience in transitioning companies from the private to public markets as well as raising capital, particularly for early stage start-ups in the biotech and life sciences space.
Colin StewartIndustry Advisor
Colin has been a Wall Street executive for 22 years and has spent his career building global businesses. Based in New York and Tokyo, he has worked for Goldman Sachs, Nomura, and CLSA. In 2010, he led CLSA’s U.S. equities division before taking responsibility for guiding the firm’s overall revenue strategy in North America. Since leaving institutional public markets in 2016, he has helped build software start-ups in the payments, software, leisure, and logistics spaces.
Ian TalmageIndustry Advisor
Ian is a Former Global Head of Global Marketing for Novartis Pharma, Senior VP Global Marketing Bayer Pharmaceutical and Head of Global Strategic Marketing for Astra.
We are proud to support these industry associations in the proteomics, mass spectrometry, and personalized medicine sectors by actively participating in their annual meetings, events, and learning opportunities. We look forward to meeting you at upcoming Events.